Stay updated with breaking news from Blood Disorders Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Far more often than he would like, 16-year-old Drew Agahiu finds himself sidelined, physically depleted and wracked with pain. But Oishei Children's Hospital has been there for him since he
Over $10 million has been raised for cancer organizations in Western New York since 2017.
Team "We're All In" is one of the many teams pushing a message of unity.
The study will be the first to use tumor infiltrating lymphocyte therapy to address certain pediatric cancers.
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.